Genmab A/S or Jazz Pharmaceuticals plc: Who Manages SG&A Costs Better?

SG&A Cost Management: Genmab vs. Jazz Pharmaceuticals

__timestampGenmab A/SJazz Pharmaceuticals plc
Wednesday, January 1, 201479529000406114000
Thursday, January 1, 201591224000449119000
Friday, January 1, 2016102413000502892000
Sunday, January 1, 2017146987000544156000
Monday, January 1, 2018213695000683530000
Tuesday, January 1, 2019342000000736942000
Wednesday, January 1, 2020661000000854233000
Friday, January 1, 202112830000001451683000
Saturday, January 1, 202226760000001416967000
Sunday, January 1, 202332970000001343105000
Monday, January 1, 20243790000000
Loading chart...

Unlocking the unknown

Managing SG&A Costs: Genmab A/S vs. Jazz Pharmaceuticals plc

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Genmab A/S and Jazz Pharmaceuticals plc have shown contrasting trends in their SG&A management. From 2014 to 2023, Genmab A/S's SG&A expenses surged by over 4,000%, peaking at approximately $3.3 billion in 2023. In contrast, Jazz Pharmaceuticals plc maintained a more stable trajectory, with a modest increase of around 230% over the same period, reaching about $1.34 billion in 2023.

This stark difference highlights Genmab's aggressive expansion strategy, possibly investing heavily in marketing and administrative capabilities. Meanwhile, Jazz Pharmaceuticals appears to have adopted a more conservative approach, focusing on steady growth. Understanding these strategies provides valuable insights into how these companies navigate the complex pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025